A New Panel-Estimated GFR, Including β2-Microglobulin and β-Trace Protein and Not Including Race, Developed in a Diverse Population
- PMID: 33301877
- PMCID: PMC8102017
- DOI: 10.1053/j.ajkd.2020.11.005
A New Panel-Estimated GFR, Including β2-Microglobulin and β-Trace Protein and Not Including Race, Developed in a Diverse Population
Erratum in
-
Erratum regarding "A New Panel-Estimated GFR, Including β2-Microglobulin and β-Trace Protein and Not Including Race, Developed in a Diverse Population" (Am J Kidney Dis. 2021;77(5):673-683).Am J Kidney Dis. 2024 Jun;83(6):840. doi: 10.1053/j.ajkd.2024.04.003. Am J Kidney Dis. 2024. PMID: 38782535 No abstract available.
Abstract
Rationale and objective: Glomerular filtration rate (GFR) estimation based on creatinine and cystatin C (eGFRcr-cys) is more accurate than estimated GFR (eGFR) based on creatinine or cystatin C alone (eGFRcr or eGFRcys, respectively), but the inclusion of creatinine in eGFRcr-cys requires specification of a person's race. β2-Microglobulin (B2M) and β-trace protein (BTP) are alternative filtration markers that appear to be less influenced by race than creatinine is.
Study design: Study of diagnostic test accuracy.
Setting and participants: Development in a pooled population of 7 studies with 5,017 participants with and without chronic kidney disease. External validation in a pooled population of 7 other studies with 2,245 participants.
Tests compared: Panel eGFR using B2M and BTP in addition to cystatin C (3-marker panel) or creatinine and cystatin C (4-marker panel) with and without age and sex or race.
Outcomes: GFR measured as the urinary clearance of iothalamate, plasma clearance of iohexol, or plasma clearance of [51Cr]EDTA.
Results: Mean measured GFRs were 58.1 and 83.2 mL/min/1.73 m2, and the proportions of Black participants were 38.6% and 24.0%, in the development and validation populations, respectively. In development, addition of age and sex improved the performance of all equations compared with equations without age and sex, but addition of race did not further improve the performance. In validation, the 4-marker panels were more accurate than the 3-marker panels (P < 0.001). The 3-marker panel without race was more accurate than eGFRcys (percentage of estimates greater than 30% different from measured GFR [1 - P30] of 15.6% vs 17.4%; P = 0.01), and the 4-marker panel without race was as accurate as eGFRcr-cys (1 - P30 of 8.6% vs 9.4%; P = 0.2). Results were generally consistent across subgroups.
Limitations: No representation of participants with severe comorbid illness and from geographic areas outside of North America and Europe.
Conclusions: The 4-marker panel eGFR is as accurate as eGFRcr-cys without requiring specification of race. A more accurate race-free eGFR could be an important advance.
Keywords: African American; Black race; GFR estimation; Glomerular filtration rate (GFR); bias; creatinine; cystatin C; estimating equations; filtration marker; kidney disease diagnosis; laboratory testing; race; race-based medicine; renal function; β(2)-microglobulin (B2M); β-trace protein (BTP).
Copyright © 2020 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Figures

Comment in
-
In Reply to "Multiple-Biomarker Panel Estimated GFR Is Not Optimal or Cost-Effective" and "Comparing Multiple-Biomarker Panels for Estimating GFR With Estimating Equations Without a Coefficient Distinguishing Black Individuals From Persons of Other Groups".Am J Kidney Dis. 2021 May;77(5):824. doi: 10.1053/j.ajkd.2021.01.007. Epub 2021 Feb 8. Am J Kidney Dis. 2021. PMID: 33571578 No abstract available.
-
Multiple-Biomarker Panel Estimated GFR Is Not Optimal or Cost-Effective.Am J Kidney Dis. 2021 May;77(5):823. doi: 10.1053/j.ajkd.2020.12.015. Epub 2021 Feb 8. Am J Kidney Dis. 2021. PMID: 33571579 No abstract available.
-
Comparing Multiple-Biomarker Panels for Estimating GFR With Estimating Equations Without a Coefficient Distinguishing Black Individuals From Persons of Other Groups.Am J Kidney Dis. 2021 May;77(5):823-824. doi: 10.1053/j.ajkd.2020.12.016. Epub 2021 Feb 8. Am J Kidney Dis. 2021. PMID: 33571580 No abstract available.
-
Race-Free Biomarkers to Quantify Kidney Function: Health Equity Lessons Learned From Population-Based Research.Am J Kidney Dis. 2021 May;77(5):667-669. doi: 10.1053/j.ajkd.2020.12.001. Epub 2021 Feb 11. Am J Kidney Dis. 2021. PMID: 33583623 No abstract available.
Similar articles
-
Glomerular Filtration Rate Estimation Using β2-Microglobulin and β-Trace Protein in Adults With Solid Tumors: A Prospective Cross-Sectional Study.Am J Kidney Dis. 2024 Sep;84(3):339-348.e1. doi: 10.1053/j.ajkd.2024.01.532. Epub 2024 Mar 26. Am J Kidney Dis. 2024. PMID: 38537905
-
GFR Estimation Using β-Trace Protein and β2-Microglobulin in CKD.Am J Kidney Dis. 2016 Jan;67(1):40-8. doi: 10.1053/j.ajkd.2015.07.025. Epub 2015 Sep 9. Am J Kidney Dis. 2016. PMID: 26362696 Free PMC article.
-
Non-GFR Determinants of Low-Molecular-Weight Serum Protein Filtration Markers in the Elderly: AGES-Kidney and MESA-Kidney.Am J Kidney Dis. 2017 Sep;70(3):406-414. doi: 10.1053/j.ajkd.2017.03.021. Epub 2017 May 24. Am J Kidney Dis. 2017. PMID: 28549536 Free PMC article.
-
Measuring and Assessing Kidney Function.Semin Nephrol. 2016 Jul;36(4):262-72. doi: 10.1016/j.semnephrol.2016.05.003. Semin Nephrol. 2016. PMID: 27475657 Review.
-
A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease.Am J Kidney Dis. 2022 Feb;79(2):268-288.e1. doi: 10.1053/j.ajkd.2021.08.003. Epub 2021 Sep 23. Am J Kidney Dis. 2022. PMID: 34563581 Review.
Cited by
-
Reassessing the Inclusion of Race in Diagnosing Kidney Diseases: An Interim Report From the NKF-ASN Task Force.Am J Kidney Dis. 2021 Jul;78(1):103-115. doi: 10.1053/j.ajkd.2021.03.008. Epub 2021 Apr 9. Am J Kidney Dis. 2021. PMID: 33845065 Free PMC article.
-
Evaluation of Race-Neutral Glomerular Filtration Rate Estimating Equations in an Indian Population.Kidney Int Rep. 2024 Oct 10;9(12):3414-3426. doi: 10.1016/j.ekir.2024.09.020. eCollection 2024 Dec. Kidney Int Rep. 2024. PMID: 39698357 Free PMC article.
-
CKD Prevalence and Incidence in Older Adults Using Estimated GFR With Different Filtration Markers: The Atherosclerosis Risk in Communities Study.Kidney Med. 2024 Aug 14;6(10):100893. doi: 10.1016/j.xkme.2024.100893. eCollection 2024 Oct. Kidney Med. 2024. PMID: 39319210 Free PMC article.
-
Role of Estimated Glomerular Filtration Rate in Clinical Research: The Never-Ending Matter.Rev Cardiovasc Med. 2024 Jan 4;25(1):1. doi: 10.31083/j.rcm2501001. eCollection 2024 Jan. Rev Cardiovasc Med. 2024. PMID: 39077647 Free PMC article. Review.
-
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.Nat Med. 2024 Jul;30(7):2058-2066. doi: 10.1038/s41591-024-03015-5. Epub 2024 May 25. Nat Med. 2024. PMID: 38796653 Free PMC article. Clinical Trial.
References
-
- Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function--measured and estimated glomerular filtration rate. The New England journal of medicine. June 08 2006;354(23):2473–2483. - PubMed
-
- College of American Pathologists. Current Status Of Reporting Estimated Glomerular Filtration Rate (eGFR). 2012; http://www.cap.org/apps/cap.portal?_nfpb=true&cntvwrPtlt_actionOverride=.... Accessed October 8, 2013.
-
- Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3(1):1–150. - PubMed
-
- Kervella D, Lemoine S, Sens F, et al. Cystatin C Versus Creatinine for GFR Estimation in CKD Due to Heart Failure. Am J Kidney Dis. February 2017;69(2):321–323. - PubMed
-
- Torre A, Aguirre-Valadez JM, Arreola-Guerra JM, et al. Creatinine Versus Cystatin C for Estimating GFR in Patients With Liver Cirrhosis. Am J Kidney Dis. February 2016;67(2):342–344. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- N01 HC095168/HL/NHLBI NIH HHS/United States
- UL1 RR024131/RR/NCRR NIH HHS/United States
- R01 DK097020/DK/NIDDK NIH HHS/United States
- UL1 TR000003/TR/NCATS NIH HHS/United States
- HHSN268201500003I/HL/NHLBI NIH HHS/United States
- N01 HC095166/HL/NHLBI NIH HHS/United States
- U01 DK066013/DK/NIDDK NIH HHS/United States
- UL1 RR029879/RR/NCRR NIH HHS/United States
- U01 DK061028/DK/NIDDK NIH HHS/United States
- UL1 TR000433/TR/NCATS NIH HHS/United States
- M01 RR000400/RR/NCRR NIH HHS/United States
- U01 HL146333/HL/NHLBI NIH HHS/United States
- 75N92020D00002/HL/NHLBI NIH HHS/United States
- HHSN268201500003C/HL/NHLBI NIH HHS/United States
- UL1 TR003096/TR/NCATS NIH HHS/United States
- U01 DK045388/DK/NIDDK NIH HHS/United States
- N01 HC095161/HL/NHLBI NIH HHS/United States
- 75N92020D00005/HL/NHLBI NIH HHS/United States
- U01 DK035073/DK/NIDDK NIH HHS/United States
- R01 DK125252/DK/NIDDK NIH HHS/United States
- K24 DK002651/DK/NIDDK NIH HHS/United States
- UL1 TR002548/TR/NCATS NIH HHS/United States
- UL1 TR001105/TR/NCATS NIH HHS/United States
- U01 DK060984/DK/NIDDK NIH HHS/United States
- U01 DK061021/DK/NIDDK NIH HHS/United States
- UL1 TR001079/TR/NCATS NIH HHS/United States
- N01 HC095169/HL/NHLBI NIH HHS/United States
- UL1 TR002494/TR/NCATS NIH HHS/United States
- K01 DK092353/DK/NIDDK NIH HHS/United States
- R01 DK082447/DK/NIDDK NIH HHS/United States
- U24 DK060990/DK/NIDDK NIH HHS/United States
- 75N92020D00001/HL/NHLBI NIH HHS/United States
- P30 GM103337/GM/NIGMS NIH HHS/United States
- U01 DK060980/DK/NIDDK NIH HHS/United States
- UC4 DK101108/DK/NIDDK NIH HHS/United States
- U01 DK060963/DK/NIDDK NIH HHS/United States
- U01 HL146208/HL/NHLBI NIH HHS/United States
- UL1 RR025752/RR/NCRR NIH HHS/United States
- P30 AG024824/AG/NIA NIH HHS/United States
- P60 AG008808/AG/NIA NIH HHS/United States
- N01 HC095167/HL/NHLBI NIH HHS/United States
- N01 HC095159/HL/NHLBI NIH HHS/United States
- 75N92020D00003/HL/NHLBI NIH HHS/United States
- M01 RR000071/RR/NCRR NIH HHS/United States
- UL1 TR001422/TR/NCATS NIH HHS/United States
- U01 DK061022/DK/NIDDK NIH HHS/United States
- P30 DK036836/DK/NIDDK NIH HHS/United States
- UL1 TR000439/TR/NCATS NIH HHS/United States
- U01 HL146201/HL/NHLBI NIH HHS/United States
- UL1 RR025777/RR/NCRR NIH HHS/United States
- U01 HL146193/HL/NHLBI NIH HHS/United States
- 75N92020D00004/HL/NHLBI NIH HHS/United States
- R34 DK097808/DK/NIDDK NIH HHS/United States
- UL1 TR001420/TR/NCATS NIH HHS/United States
- UL1 TR000424/TR/NCATS NIH HHS/United States
- M01 RR016500/RR/NCRR NIH HHS/United States
- N01 HC095163/HL/NHLBI NIH HHS/United States
- 75N92020D00007/HL/NHLBI NIH HHS/United States
- U01 DK060902/DK/NIDDK NIH HHS/United States
- U01 DK053869/DK/NIDDK NIH HHS/United States
- U01 DK060990/DK/NIDDK NIH HHS/United States
- UL1 TR002319/TR/NCATS NIH HHS/United States
- UL1 TR002556/TR/NCATS NIH HHS/United States
- UL1 RR029887/RR/NCRR NIH HHS/United States
- P30 DK020572/DK/NIDDK NIH HHS/United States
- R01 DK051975/DK/NIDDK NIH HHS/United States
- UL1 TR000040/TR/NCATS NIH HHS/United States
- N01 HC095162/HL/NHLBI NIH HHS/United States
- 75N92020D00006/HL/NHLBI NIH HHS/United States
- N01 HC095165/HL/NHLBI NIH HHS/United States
- U01 HL146240/HL/NHLBI NIH HHS/United States
- N01 HC095164/HL/NHLBI NIH HHS/United States
- R03 DK094484/DK/NIDDK NIH HHS/United States
- UL1 TR003098/TR/NCATS NIH HHS/United States
- N01 HC095160/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous